

**SUPPLEMENTARY MATERIAL: Switch from intravenous to subcutaneous
immunoglobulin in CIDP and MMN – 12 months results from an observational study**

Stefan Gingele ^{1#,*}, Anna Christina Saparilla Pietschmann ^{1#}, Konstantin F. Jendretzky ¹,
Moritz Koch ¹, Gudrun M. Körner ^{1,2}, Janna M. Siemer ¹, Franz Felix Konen ¹, Martin W.
Hümmert ¹, Friederike Salge ¹, Jarle von Hörsten ¹, Tabea Seeliger ¹, Sonja Körner ¹, and
Thomas Skripuletz ¹

¹ *Department of Neurology, Hannover Medical School, Hannover, Germany*

² *Department of Neurology, University Hospital Zürich, 8091 Zürich, Switzerland.*

[#] These authors contributed equally to this work.

*Corresponding author:

Dr. med. Stefan Gingele

Department of Neurology

Hannover Medical School

Carl-Neuberg-Str. 1, 30625 Hannover, Germany

Ph.: +49 511 532 3816

Fax: +49 511 532 3115

E-mail: gingele.stefan@mh-hannover.de

Supplementary material. Nerve conduction studies.

	CIDP			MMN		
	n	change after 12 months	p	n	change after 12 months	p
Peroneal nerve						
DML [ms]/ 6.5-13 cm	43	-0.23 (2.78)	0.220	9	+0.57 (2.05)	0.906
CMAP distal [mV]	43	-0.22 (1.71)	0.299	9	+0.44 (1.52)	0.406
MCV lower leg [m/s]	42	-0.43 (5.95)	0.643	9	+2.78 (6.98)	0.266
CMAP lower leg [mV]	42	-0.32 (1.40)	0.06	9	+0.39 (2.29)	0.624
FWL [ms]	26	+1.15 (7.89)	0.466	6	+2.12 (4.10)	0.581
Tibial nerve						
DML [ms]/ 7-11 cm	35	-0.05 (1.50)	0.439	8	-0.20 (0.77)	0.487
CMAP distal [mV]	35	-0.12 (2.22)	0.350	8	+0.60 (1.63)	0.333
MCV lower leg [m/s]	34	+0.71 (5.65)	0.247	8	+0.25 (5.50)	0.901
CMAP lower leg [mV]	34	+0.80 (1.74)	0.003	8	+0.71 (1.43)	0.203
FWL [ms]	28	+1.07 (10.75)	0.628	8	+2.03 (8.79)	0.536
Median nerve						
DML [ms]/ 7-8 cm	44	+0.11 (1.42)	0.309	8	+0.24 (0.70)	0.531
CMAP distal [mV]	44	+0.39 (2.15)	0.235	8	+0.14 (1.01)	0.710
MCV forearm [m/s]	44	-0.02 (9.59)	0.567	8	+3.50 (9.65)	0.339
FWL [ms]	35	+0.52 (6.35)	0.688	6	+1.05 (2.70)	0.438

Supplementary Material. Nerve conduction studies.

Apart from a significant higher composite muscle action potential (CMAP) for the tibial nerve after 12 months, nerve conduction studies showed stable findings over a period of 12 months of SCIG therapy. Values are given as mean with standard deviation (SD).

Abbreviations: CIDP: chronic inflammatory demyelinating polyneuropathy; MMN: multifocal motor neuropathy; DML: distal motor latency; CMAP: composite muscle action potential; MCV: motor conduction velocity; FWL: F-wave latency.